Prognostic significance of serum alkaline phosphatase activity in canine appendicular osteosarcoma

Journal of veterinary internal medicine / American College of Veterinary Internal Medicine

Volumn 14, Issue 6, 2000, Pages 587-592

  Garzotto, Caroline K ^a   Berg, John ^a   Hoffmann, Walter E ^c   Rand, William M ^b  

^a TUFTS UNIVERSITY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; ISOENZYME;

AGE; AMPUTATION; ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; BONE TUMOR; DOG; DOG DISEASE; ENZYMOLOGY; OSTEOSARCOMA; PREDICTION AND FORECASTING; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZATION; SURVIVAL RATE;

AGE FACTORS; ALKALINE PHOSPHATASE; AMPUTATION; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CISPLATIN; DOG DISEASES; DOGS; DOXORUBICIN; ISOENZYMES; OSTEOSARCOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RANDOM ALLOCATION; SURVIVAL RATE;

EID: 0034329889     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2000.tb02281.x     Document Type: Article

References (28)

1. 1 Spodnick GJ, Berg J., Rand WM, et al. Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978–1988). J Am Vet Med Assoc 1992 ; 200: 995–999.
2. 2 Berg J., Weinstein MJ, Springfield DS, Rand WM. Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. J Am Vet Med Assoc 1995 ; 206: 1555–1560.
3. 3 Shapiro W., Fossum TW, Kitchell BE, et al. Use of cisplatin for treatment of appendicular osteosarcoma in dogs. J Am Vet Med Assoc 1988 ; 192: 507–511.
4. 4 Kraegel SA, Madewell BR, Simonson E., et al. Osteogenic sarcoma and cisplatin chemotherapy in dogs: 16 cases (1986–1989). J Am Vet Med Assoc 1991 ; 199: 1057–1059.
5. 5 Straw RC, Withrow SJ, Richter SL, et al. Amputation and cisplatin for treatment of canine osteosarcoma. J Vet Intern Med 1991 ; 5: 205–210.
6. 6 Thompson JP, Fugent MJ. Evaluation of survival times after limb amputation, with and without subsequent administration of cisplatin, for treatment of appendicular osteosarcoma in dogs: 30 cases (1979–1990). J Am Vet Med Assoc 1992 ; 200: 531–533.
7. 7 Berg J., Weinstein MJ, Schelling SH, Rand WM. Treatment of dogs with osteosarcoma by administration of cisplatin after amputation or limb‐sparing surgery: 22 cases (1987–1990). J Am Vet Med Assoc 1992 ; 200: 2005–2008.
8. 8 Bergman PJ, MacEwen EG, Kurzman ID, et al. Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). J Vet Intern Med 1996 ; 10: 76–81.
9. 9 Forrest LJ, Dodge RK, Page RL, et al. Relationship between quantitative tumor scintigraphy and time to metastasis in dogs with osteosarcoma. J Nucl Med 1992 ; 33: 1542–1547.
10. 10 Weinstein MJ, Berg J., Kusuzaki K., et al. In vitro assay of nuclear uptake of doxorubicin hydrochloride in osteosarcoma cells of dogs. Am J Vet Res 1991 ; 52: 1951–1955.
11. 11 Coomber BL, Denton J., Sylvestre A., Kruth S. Blood vessel density in canine osteosarcoma. Can J Vet Res 1998 ; 62: 199–204.
12. 12 Ehrhart N., Dernell WS, Hoffmann WE, et al. Prognostic importance of alkaline phosphatase activity in serum from dogs with appendicular osteosarcoma: 75 cases (1990–1996). J Am Vet Med Assoc 1998 ; 213: 1002–1006.
13. 13 Kramer JW, Hoffmann WE. Clinical enzymology. In: Clinical Biochemistry of Domestic Animals, 5th ed. San Diego, CA: Academic Press ; 1997: 303–325.
14. 14 McKenna RJ, Schwin CP, Soong KL, et al. Sarcomata of osteogenic series: analysis of 553 cases. J Bone Joint Surg Am 1966 ; 48: 1–26.
15. 15 Thorpe WP, Reilly JJ, Rosenberg SA. Prognostic significance of alkaline phosphatase measurements in patients with osteogenic sarcoma receiving chemotherapy. Cancer 1979 ; 43: 2178–2181.
16. 16 Bacci G., Picci P., Orlandi M., et al. Prognostic value of serum alkaline phosphatase in osteosarcoma. Tumori 1987 ; 73: 331–336.
17. 17 Bacci G., Picci P., Ferrari S., et al. Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy. Cancer 1993 ; 71: 1224–1230.
18. 18 Levine AM, Rosenberg SA. Alkaline phosphatase levels in osteosarcoma tissue are related to prognosis. Cancer 1979 ; 44: 2291–2293.
19. 19 Liu PP, Leung KS, Kumta SM, et al. Bone specific alkaline phosphatase as a tumour marker for osteosarcoma. Oncology 1996 ; 53: 275–280.
20. 20 Leung KS, Fung KP, Sher AHL, et al. Plasma bone‐specific alkaline phosphatase as an indicator of osteoblastic activity. J Bone Joint Surg Br 1992 ; 75: 288–292.
21. 21 Allen MJ, Hoffmann WE, Richardson DC, Breur GJ. Serum markers of bone metabolism in dogs. Am J Vet Res 1998 ; 59: 250–254.
22. 22 Sanecki RK, Hoffmann WE, Hansen R., et al. Quantification of bone alkaline phosphatase in canine serum. Vet Clin Pathol 1993 ; 22: 17–23.
23. 23 Berg J., Gebhardt MC, Rand WM. Effect of timing of postoperative chemotherapy on survival of dogs with osteosarcoma. Cancer 1997 ; 79: 1343–1350.
24. 24 Ogilvie GK, Krawiec DR, Gelberg HB, et al. Evaluation of a short‐term diuresis protocol for the administration of cisplatin. Am J Vet Res 1988 ; 49: 1076–1078.
25. 25 Owen LN. Cancer chemotherapy and immunotherapy. In: Ettin‐ger SJ, ed. Textbook of Veterinary Internal Medicine, 2nd ed. Philadelphia, PA: WB Saunders ; 1983: 368–392.
26. 26 Allen LCV, Allen MJ, Breur GJ, et al. A comparison of two techniques for the determination of serum bone‐specific alkaline phosphatase activity in dogs. Res Vet Sci 2000 ; 68: 231–235.
27. 27 Ali NN, Rowe J., Teich NM. Constitutive expression of non‐bone/liver/kidney alkaline phosphatase in human osteosarcoma cell lines. J Bone Miner Res 1996 ; 11: 512–520.
28. 28 Simon R. Design and conduct of clinical trials. In: DeVita VT, ed. Cancer: Principles and Practice of Oncology. Philadelphia, PA: JB Lippincott ; 1993: 418–440.